Effect of vitamin D treatment on serum sclerostin level

Basit Öğe Kaydı
dc.contributor.authorAcıbucu, Fettah
dc.contributor.authorDökmetaş, Hatice Sebila
dc.contributor.authorOğuz Acıbucu, Duygu
dc.contributor.authorKılıçlı, Fatih
dc.contributor.authorAydemir, Mikail
dc.contributor.authorÇakmak, Ecir Ali
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:55:58Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:55:58Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000413852500008
dc.descriptionPubMed ID: 26824280
dc.description.abstractObjective Sclerostin is an osteocyte-secreted endogenous inhibitor of Wnt signaling. Several systemic and local factors have been suggested as possible regulators of sclerostin expression by osteocytes. In this study, we examined the effect of vitamin D treatment on sclerostin levels. Subject and Methods 44 patients with diagnosis of vitamin D deficiency (25(OH)D20ng/ml) were involved in the study. Patients had monthly intramuscular injection of 300.000IU cholecalciferol for 3 consecutive months. Sclerostin, 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus and alkaline phosphatase (ALP) levels were measured during the diagnosis and after the replacement of vitamin D. Results 8 male and 36 female patients were enrolled in the study. Minimum age, maximum age and average age were 21, 55 and 32.02 +/- 9.26 years, respectively. A statistically significant difference was observed between the pre-treatment and post-treatment values in 25(OH)D levels (p:0.001, 10.27 +/- 4.62ng/ml and 51.40 +/- 14.62ng/ml, respectively), PTH levels (p:0.001, 50.32 +/- 19.05pg/ml and 33.97 +/- 13.12pg/ml, respectively) and sclerostin levels (p:0.002, 858.98 +/- 351.63pg/ml and 689.52 +/- 197.92pg/ml, respectively). No statistically significant difference, however, was found between the pre-treatment and post-treatment calcium, phosphorus and ALP levels. Correlation analysis made on pre-treatment and post-treatment sclerostin levels and 25(OH)D, PTH, calcium, phosphorus and ALP levels revealed no statistically significant correlation. Conclusion Our findings show that the sclerostin level of patients with vitamin D deficiency decreases considerably through treatment.
dc.identifier.citationAcıbucu, F., Dökmetaş, H. S., Oğuz Acıbucu, D., Kılıçlı, F., Aydemir, M. ve Çakmak, E. A. (2017). Effect of vitamin D treatment on serum sclerostin level. Experimental and Clinical Endocrinology & Diabetes, 125(9), 634-637. https://dx.doi.org/10.1055/s-0035-1559790
dc.identifier.doi10.1055/s-0035-1559790
dc.identifier.endpage637
dc.identifier.issn0947-7349
dc.identifier.issn1439-3646
dc.identifier.issue9
dc.identifier.scopusqualityQ2
dc.identifier.startpage634
dc.identifier.urihttps://dx.doi.org/10.1055/s-0035-1559790
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2502
dc.identifier.volume125
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherJohann Ambrosius Barth Verlag Medizinverlage Heidelberg GMBH
dc.relation.ispartofExperimental and Clinical Endocrinology & Diabetesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSclerostin
dc.subjectVitamin D Deficiency
dc.subjectParathyroid Hormone
dc.titleEffect of vitamin D treatment on serum sclerostin level
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu